Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

ulixertinib 1tislelizumab 1talazoparib 1serabelisib 1sapanisertib 1pembrolizumab 1olaparib 1mirdametinib 1lenvatinib 1erdafitinib 1crenigacestat 1atezolizumab 1Ramucirumab 1Paclitaxel 1PM 01183 1Injections 1IFL protocol 1Gemcitabine 1Bosentan 1BID protein, human 1Appointments and Schedules 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Solid Tumor × crenigacestat × Clear all
NCT02836600 2025-08-07

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
11 enrolled 9 charts
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡